Retatrutide Buccal Strips Research: RT3, Triple-Receptor Signaling, Buccal Formulation, Delivery Comparison, Metabolic Models, and Evidence Limits

RT3 buccal strips are studied in peptide research as a buccal film form of retatrutide, a triple-agonist peptide that acts at GLP-1, GIP and glucagon receptors at once, with 1mg of retatrutide in each film and 8 films in a box.

Retatrutide is a peptide studied for appetite regulation, energy balance, metabolic rate, fat metabolism, and body composition in metabolic research. For the background on retatrutide itself, see Retatrutide research.

This article on Retatrutide buccal strips research is presented as research material only. It does not diagnose, treat, cure, or prevent any disease, does not recommend use in people, and does not present buccal strips as an approved drug or supplement for human consumption.

What Retatrutide Is, in Research

Retatrutide is a single peptide that acts at three receptors at once: GLP-1, GIP and glucagon. That triple action is what separates it in research from single-receptor peptides, and from dual-agonist peptides such as tirzepatide. The three pathways are studied together for appetite regulation and energy balance, through GLP-1 and GIP, and for metabolic rate and fat metabolism, through glucagon receptor activity.

The compound is identified on the product page as retatrutide (LY3437943), CAS 2381089-83-2, molecular formula C221H342N46O68, molecular weight about 4,731 g/mol, purity at least 99%, with a per-lot Certificate of Analysis available on request. Those identifiers matter in research because retatrutide is also discussed under the name RT3, and the two names refer to the same compound.

Human evidence for retatrutide comes mainly from Phase 2 studies and the TRIUMPH Phase 3 programme, which are covered in Retatrutide research. Those studies used injected retatrutide, not a buccal film, and their results cannot be transferred directly to a buccal film without buccal delivery evidence.

What a Buccal Strip Changes

A buccal strip is a thin film placed in the mouth, where it dissolves and its contents are absorbed through the oral mucosa rather than through the digestive tract. For a peptide, that route is studied because peptides are normally broken down in the gut, and swallowing a peptide does not establish the same exposure as buccal absorption.

The RT3 film contains 1mg of retatrutide per film, with 8 films in a box. The film ingredients on the product page are pullulan, HPMC (hydroxypropyl methylcellulose), stevia glycosides, glycerin, citric acid, xanthan gum, gum arabic, sunflower lecithin, blood orange flavour extract, and natural orange colour. The film is described as vegan, sugar-free, gluten-free, naturally flavoured, and made in the USA in a GMP facility, with no dyes, preservatives, or unnecessary fillers.

How RT3 buccal strips are studied in peptide research, including what a film form adds to the compound research, is set out in How RT3 Buccal Strips Are Studied in Peptide Research.

Formulation and Film Stability

Formulation research for a buccal film looks at how the peptide is held in the film, how the film dissolves, and how the film holds up in storage. A film that dissolves too fast, too slowly, or unevenly changes the exposure, and a film that loses peptide content in storage changes the amount that is actually present.

Storage on the product page is sealed, in a cool, dry place, away from direct light. That is a storage condition for the product, not a research finding about stability, and film stability research is read separately, in controlled storage conditions, over time.

Film stability, and the difference between film stability in storage and peptide stability in general, are covered in the formulation and stability articles linked from this page.

Buccal Delivery Compared With Other Forms

Buccal delivery is compared in research with injection, with swallowing, and with other mucosal routes. Injection gives a known systemic exposure, swallowing gives gut breakdown for most peptides, and buccal delivery sits between them: absorption through the mouth lining, with some loss from swallowing and saliva.

No published human buccal pharmacokinetic study for retatrutide was reviewed for this article, and a buccal film result should not be read as if it were an injection result. The comparison is about delivery, not about effect: a delivery route can change exposure without changing the compound, and exposure must be measured before any metabolic reading is made.

How RT3 buccal delivery is compared with other delivery forms in peptide research, and how buccal absorption is studied step by step, are set out in How RT3 Buccal Delivery Is Compared With Other Delivery Forms in Peptide Research.

Metabolic Models

Retatrutide is studied in metabolic models for appetite and energy balance, for metabolic rate and fat metabolism, and for body composition. Those are three different readings, and they do not establish each other: an appetite measure does not establish a fat metabolism measure, and a body composition measure in an animal model does not establish the same measure in people.

Buccal film research in these models is read at the film level first: did the film dissolve, was the peptide absorbed, and was exposure measured. Only then is the metabolic reading made, and only for the model and the measures actually used.

How RT3 buccal films are studied in appetite and energy balance models, in metabolic rate and fat metabolism models, and in body composition models, is set out in How RT3 Buccal Films Are Studied in Appetite and Energy Balance Models in Peptide Research.

Stacks

RT3 is also studied in stack research, where it is combined with other peptides and the result is read for the combination, not for RT3 alone. A stack result cannot be separated into a RT3 result and a MOTS-c result, or a RT3 result and a CJC-1295/Ipamorelin result, without a design that isolates each component.

The stacks on the product page are Body Composition, with MOTS-c and CJC-1295/Ipamorelin, Metabolic Duo, with MOTS-c, and Complete Longevity, with NAD+, MOTS-c, BPC-157/TB-500 and Thymosin Alpha-1. How those stack results should be separated from a RT3 result is set out in How RT3 Fits Into Body Composition and Metabolic Duo Stack Research.

External Evidence

Retatrutide literature, as reviewed for this article, is centred on triple-receptor agonism at GLP-1, GIP and glucagon receptors, metabolic effects in animal and human models, Phase 2 studies, and the TRIUMPH Phase 3 programme, with human evidence from injected retatrutide, used here only as compound background, not as buccal film evidence.

Buccal peptide delivery literature, as reviewed for this article, is centred on dissolution, mucosal permeation, and swallowing loss, in laboratory and animal models, and should be read as such. No published human buccal pharmacokinetic study for retatrutide was found that tested a RT3 buccal film, for exposure, in people.

What Retatrutide Buccal Strips Research Can Establish

• The identity and purity of retatrutide in a film, with the compound identifiers stated on the product page.
• How a buccal film containing retatrutide is made, how it dissolves, and how it holds up under controlled storage.
• How buccal absorption is studied, in vitro and in animal models, for a peptide film.
• How a buccal film result is read in appetite, metabolic rate, fat metabolism, and body composition models, for the model and the measures actually used.
• Whether a stack result can be read for RT3, or only for the combination, with a design that separates the components.

What Retatrutide Buccal Strips Research Does Not Establish

• That a buccal film improves appetite regulation, energy balance, metabolic rate, fat metabolism, or body composition in people.
• That a buccal film result is the same as an injection result, without a buccal pharmacokinetic study in people.
• That a metabolic measure in one model, with one measure, applies to another model, another measure, or another form.
• That a stack result is a RT3 result, without a RT3 alone group, or a RT3 removal group, in the same model, with the same measures.
• That a buccal strip is an approved drug or supplement for human use.

Final Perspective

Retatrutide buccal strips are a film form of a triple-agonist peptide that is already well studied as an injected compound. The film adds a delivery question, not a new compound question, and the research value of the film is in how it is made, how it holds up, how it is absorbed, and how its results are read in metabolic models, with the limits of buccal evidence kept in view.

For how RT3 buccal strips are studied in peptide research, see how RT3 buccal strips are studied in peptide research.

Related product: RT3 Buccal Strips 1mg, 8 count, research material. Details on the product page.